Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company. The group is engaged in the research, development and manufacture of proprietary abuse deterrent, abuse resistant and tamper resistant formulations. Acura Pharmaceuticals abuse deterrent formulations are intended for use in orally administered opioid-containing prescription analgesic products. The company is actively collaborating with contract research organizations for laboratory and clinical evaluation and testing of product candidates. Acura Pharmaceuticals has previously been involved in research, development and manufacture of proprietary, high-yield, short cycle time, environmentally sensitive opioid manufacturing processes. The company has since suspending its opioid synthesis technologies. Acura Pharmaceuticals, Inc. maintains its head offices in Palatine, Ill.